13 results on '"Fahed Z"'
Search Results
2. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival
- Author
-
Marie Duhamel, Lauranne Drelich, Maxence Wisztorski, Soulaimane Aboulouard, Jean-Pascal Gimeno, Nina Ogrinc, Patrick Devos, Tristan Cardon, Michael Weller, Fabienne Escande, Fahed Zairi, Claude-Alain Maurage, Émilie Le Rhun, Isabelle Fournier, and Michel Salzet
- Subjects
Science - Abstract
Characterisation of molecular heterogeneity in glioblastoma would improve patient stratification. Here, the authors integrate spatial proteomics and clinical data from glioblastoma patients and identify 3 molecular groups and a 5-protein signature that was associated with survival.
- Published
- 2022
- Full Text
- View/download PDF
3. Single Posterior Approach for Resection and Stabilization for Locally Advanced Pancoast Tumors Involving the Spine: Single Centre Experience
- Author
-
Fahed Zairi, Tarek Sunna, Moishe Liberman, Ghassan Boubez, Zhi Wang, and Daniel Shedid
- Subjects
Pancoast syndrome ,Tumor resection ,Chemotherapy ,Radiation therapy ,Medicine - Abstract
Study DesignMonocentric prospective study.PurposeTo assess the safety and effectiveness of the posterior approach for resection of advanced Pancoast tumors.Overview of LiteratureIn patients with advanced Pancoast tumors invading the spine, most surgical teams consider the combined approach to be necessary for “en-bloc” resection to control visceral, vascular, and neurological structures. We report our preliminary experience with a single-stage posterior approach.MethodsWe included all patients who underwent posterior en-bloc resection of advanced Pancoast tumors invading the spine in our institution between January 2014 and May 2015. All patients had locally advanced tumors without N2 nodes or distant metastases. All patients, except 1, benefited from induction treatment consisting of a combination of concomitant chemotherapy (cisplatin-VP16) and radiation.ResultsFive patients were included in this study. There were 2 men and 3 women with a mean age of 55 years (range, 46–61 years). The tumor involved 2 adjacent levels in 1 patient, 3 levels in 1 patient, and 4 levels in 3 patients. There were no intraoperative complications. The mean operative time was 9 hours (range, 8–12 hours), and the mean estimated blood loss was 3.2 L (range, 1.5–7 L). No patient had a worsened neurological condition at discharge. Four complications occurred in 4 patients. Three complications required reoperation and none was lethal. The mean follow-up was 15.5 months (range, 9–24 months). Four patients harbored microscopically negative margins (R0 resection) and remained disease free. One patient harbored a microscopically positive margin (R1 resection) and exhibited local recurrence at 8 months following radiation treatment.ConclusionsThe posterior approach was a valuable option that avoided the need for a second-stage operation. Induction chemoradiation is highly suitable for limiting the risk of local recurrence.
- Published
- 2016
- Full Text
- View/download PDF
4. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases
- Author
-
Emilie Le Rhun, Sophie Taillibert, Thomas Boulanger, Fahed Zairi, Jacques Bonneterre, and Marc C. Chamberlain
- Subjects
Leptomeningeal metastases ,Neoplastic meningitis ,Breast cancer ,Bevacizumab ,Quality of life ,Symptom control ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological function improve with treatment. Case Report: A 34-year-old female with hormone-negative and HER2-positive metastatic breast cancer was diagnosed with bulky radiographic LM 45 months after initial diagnosis. She was treated with intra-CSF trastuzumab followed by intra-CSF liposomal cytarabine; however, the cancer progressed 8 months after the diagnosis of LM. At the time of the third LM progression, the patient presented with a cauda equina syndrome and cerebellar impairment resulting in an inability to walk. She was treated with CNS-directed radiotherapy (lumbosacral and cerebellar) and bevacizumab plus vinorelbine. Rapid functional improvement occurred, and the patient regained the ability to walk and independently manage her daily activities. Twelve months later, she presented with rapid progression of the LM resulting in death within several weeks. Conclusion: In radiographically defined bulky LM, the combination of systemic therapy and CNS-directed radiotherapy likely is more active than intra-CSF therapy only. In lieu of the rapid and significant improvement in neurological function combined with the prolonged response, bevacizumab alone or in combination with chemotherapy and CNS-directed radiotherapy may be considered in select patients with radiographically bulky breast cancer-related LM.
- Published
- 2015
- Full Text
- View/download PDF
5. Delayed Hypersensitivity Reaction: An Increasingly Recognized Complication of Metal-on-Metal Total Disc Replacement
- Author
-
Mélodie-Anne Karnoub, Fahed Zairi, Rabih Aboukais, and Richard Assaker
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
We report the case of a 32-year-old woman who presented with pain recurrence 20 months after she underwent a C5C6 metal-on-metal total replacement. Plan radiographs demonstrated a modification of the shape of the vertebral bodies making the prosthesis more protruding. Then, infection has been ruled out and patch testing revealed a strongly positive reaction for chromium and cobalt. The prosthesis has been removed and a fusion achieved using a cage filled with bone graft. She has been immediately and fully relieved from her pain. We report the radiological signs that enabled early diagnosis and treatment allowing favorable outcome.
- Published
- 2015
- Full Text
- View/download PDF
6. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region
- Author
-
Ali Bazarbachi, Azim, H. A., Alizadeh, H., Aljurf, M., Barista, I., Chaudhri, N. A., Fahed, Z., Fahmy, O. A., Ghavamzadeh, A., Khalaf, M. H., Khatib, S., Kutoubi, A., Paydas, S., Elayoubi, H. R., Zaatari, G., Zawam, H. M., Zelenetz, A. D., and Mena, Lymphoma Regional Guidelines Committee
7. National approaches to managing cancer care: responses of countries in the MENA region to the COVID-19 pandemic.
- Author
-
Benbrahim Z, Mula-Hussain L, Al-Shamsi HO, El Saghir N, Al Asiri M, Al Bahrani B, Al Nassar M, Bounedjar A, Fahed Z, Khatib S, Khorshid O, Labidi S, Mellas N, Saleh A, and Jazieh A
- Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic presents serious challenges to cancer care because of the associated risks from the infection itself and the disruption of care delivery. Therefore, many professional societies have published recommendations to help manage patients with cancer during the current pandemic. The objective of our study is to assess the national responses of Middle East North Africa (MENA) countries in terms of publishing relevant guidelines and analyse various components of these guidelines., Methods: A survey based on the preliminary review of the literature regarding cancer care adaptations has been developed and then completed by a group of oncologists from the following Arab countries affected by the pandemic: Algeria, Egypt, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Saudi Arabia, Syria, Tunisia, United Arab Emirates and Yemen. The survey inquired about COVID-19 cases, national recommendations regarding general measures of COVID-19 prevention and patient care in oncology as well as their implementation about cancer care adaptations during the pandemic., Results: Analysis of the COVID-19 pandemic-related guidelines revealed at least 30 specific recommendations that we categorised into seven essential components. All included countries had national guidelines except one country. Estimated full compliances with all specific category recommendations ranged from 30% to 69% and partial compliance ranged from 23% to 61%., Conclusion: There is a very good response and preparedness in the Arab Middle East and North Africa region surveyed. However, there are inconsistencies in the various components of the guidelines across the region, which reflects the evolving status of the pandemic in each country as well as the lack of clear evidence-based guidelines for many of the issues in question. There is a need for a clear framework on essential components that should be included in these guidelines to assure providing the best guidance to the oncology community., Competing Interests: Zineb Benbrahim received educational grants from Novartis, MSD, AstraZeneca. Humaid O Al Shamsi received research support from ROCHE. AR Jazieh received research funds from MSD., (© the authors; licensee ecancermedicalscience.)
- Published
- 2021
- Full Text
- View/download PDF
8. Guidelines and mHealth to Improve Quality of Hypertension and Type 2 Diabetes Care for Vulnerable Populations in Lebanon: Longitudinal Cohort Study.
- Author
-
Doocy S, Paik KE, Lyles E, Hei Tam H, Fahed Z, Winkler E, Kontunen K, Mkanna A, and Burnham G
- Abstract
Background: Given the protracted nature of the crisis in Syria, the large noncommunicable disease (NCD) caseload of Syrian refugees and host Lebanese, and the high costs of providing NCD care, the implications for Lebanon's health system are vast., Objective: The aim of this study was to evaluate the effectiveness of treatment guidelines and a mobile health (mHealth) app on quality of care and health outcomes in primary care settings in Lebanon., Methods: A longitudinal cohort study was implemented from January 2015 to August 2016 to evaluate the effectiveness of treatment guidelines and an mHealth app on quality of care and health outcomes for Syrian and Lebanese patients in Lebanese primary health care (PHC) facilities., Results: Compared with baseline record extraction, recording of blood pressure (BP) readings (-11.4%, P<.001) and blood sugar measurements (-6.9%, P=.03) significantly decreased following the implementation of treatment guidelines. Recording of BP readings also decreased after the mHealth phase as compared with baseline (-8.4%, P=.001); however, recording of body mass index (BMI) reporting increased at the end of the mHealth phase from baseline (8.1%, P<.001) and the guidelines phase (7.7%, P<.001). There were a great proportion of patients for whom blood sugar, BP, weight, height, and BMI were recorded using the tablet compared with in paper records; however, only differences in BMI were statistically significant (31.6% higher in app data as compared with paper records; P<.001). Data extracted from the mHealth app showed that a higher proportion of providers offered lifestyle counseling compared with the counseling reported in patients' paper records (health diet counseling; 77.3% in app data vs 8.8% in paper records, P<.001 and physical activity counseling and 59.7% in app vs 7.1% in paper records, P<.001). There were statistically significant increases in all four measures of patient-provider interaction across study phases. Provider inquiry of medical history increased by 16.6% from baseline following guideline implementation and by 28.2% from baseline to mHealth implementation (P<.001). From baseline, patient report of provider inquiry regarding medication complications increased in the guidelines and mHealth phases by 12.9% and 59.6%, respectively, (P<.001). The proportion of patients reporting that providers asked other questions relevant to their illness increased from baseline through guidelines implementation by 27.8% and to mHealth implementation by 66.3% (P<.001). Follow-up scheduling increased from baseline to the guidelines phase by 20.6% and the mHealth phase by 39.8% (P<.001)., Conclusions: Results from this study of an mHealth app in 10 PHC facilities in Lebanon indicate that the app has potential to improve adherence to guidelines and quality of care. Further studies are necessary to determine the effects of patient-controlled health record apps on provider adherence to treatment guidelines, as well as patients' long-term medication and treatment adherence and disease control., (©Shannon Doocy, Kenneth E Paik, Emily Lyles, Hok Hei Tam, Zeina Fahed, Eric Winkler, Kaisa Kontunen, Abdalla Mkanna, Gilbert Burnham. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 18.10.2017.)
- Published
- 2017
- Full Text
- View/download PDF
9. Pilot Testing and Implementation of a mHealth tool for Non-communicable Diseases in a Humanitarian Setting.
- Author
-
Doocy S, Paik K, Lyles E, Tam HH, Fahed Z, Winkler E, Kontunen K, Mkanna A, and Burnham G
- Abstract
Introduction: Given the protracted nature of the crisis in Syria, national and international assistance agencies face immense challenges in providing for the needs of refugees and the host Lebanese due to the high burden of noncommunicable diseases (NCDs) among both populations. These are complex conditions to manage, and the resources for refugee care limited, having dramatic implications for Lebanon's health system., Methods: A longitudinal cohort study was implemented from January 2015 through August 2016 to evaluate the effectiveness of treatment guidelines and an mHealth application on quality of care and health outcomes for patients in primary health care facilities in Lebanon serving Syrian refugees and host communities., Results: Overall, reporting in clinic medical records remained low, however, during the mHealth phase recording of BMI and blood pressure were significantly greater in the mHealth application as compared to clinic medical records. Patient exit interviews reported a much more frequent measurement of weight, height, blood pressure, and blood glucose, suggesting these may be assessed more often than they are recorded. Satisfaction with the clinic visit improved significantly during implementation of the mHealth application as compared to both baseline and guidelines implementation in all measures. Despite positive changes, provider uptake of the application was low; patients indicated that the mHealth application was used in a minority (21.7%) of consultations. Provider perspectives on how the application changed patient interactions were mixed., Discussion: Similar to previous evidence, this study further demonstrates the need to incorporate new interventions with existing practices and reporting requirements to minimize duplication of efforts and, consequently, strengthen provider usage. Additional research is needed to identify organizational and provider-side factors associated with uptake of similar applications, particularly in complex settings, to optimize the benefit of such tools.
- Published
- 2017
- Full Text
- View/download PDF
10. Management of neoplastic spinal tumors in a spine surgery care unit.
- Author
-
Zairi F, Vieillard MH, Devos P, Aboukais R, Gras L, and Assaker R
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Spinal Neoplasms epidemiology, Spinal Neoplasms secondary, Orthopedic Procedures statistics & numerical data, Palliative Care statistics & numerical data, Postoperative Complications epidemiology, Spinal Neoplasms surgery
- Abstract
Background Context: Spinal cord compression and fracture are possible complications of spine metastasis and multiple myeloma. Prompt diagnosis and treatment of threatening lesions are likely to reduce the frequency of these dreaded complications., Purpose: To evaluate the proportion of neoplastic spine lesions operated on emergency., Study Design: Retrospective study., Patient Sample: All patients who underwent palliative surgery for the treatment of a neoplastic spine lesion in our institution between 2005 and 2012., Outcome Measures: Percentage of patients who underwent surgery as an emergency for acute fracture or rapid neurological decline., Methods: We retrospectively reviewed the data of all patients who underwent palliative surgery for the treatment of a neoplastic spine lesion from solid cancer or multiple myeloma, in our institution between January 2005 and December 2012. The study was supported by grant from our institution., Results: A total of 317 patients were included in the study. There were 166 men and 151 women and the mean age was 57.97 years (range 26-88; SD 12.45). The cancer was known for 224 patients, while the lesion revealed the disease for the other 93 patients. The percentage of patients with known cancer operated as an emergency in our institution decreased significantly between 2005 and 2012 (p = 0.0006)., Conclusion: Due to the variability of clinical and radiological presentations, best care requires a truly multidisciplinary approach, to offer each patient a prompt and individualized treatment option, which is likely to reduce the incidence of emergency surgeries., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
11. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
- Author
-
Otrock ZK, Mahfouz RA, Fahed Z, Farhat FS, Ziade A, Nasr F, Kassem N, and Abboud MR
- Subjects
- Antineoplastic Agents administration & dosage, Benzamides, Drug Resistance, Neoplasm, Humans, Imatinib Mesylate, Piperazines administration & dosage, Protein Kinase Inhibitors administration & dosage, Pyrimidines administration & dosage, Treatment Outcome, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Piperazines therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
- Published
- 2012
- Full Text
- View/download PDF
12. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region.
- Author
-
Bazarbachi A, Azim HA, Alizadeh H, Aljurf M, Barista I, Chaudhri NA, Fahed Z, Fahmy OA, Ghavamzadeh A, Khalaf MH, Khatib S, Kutoubi A, Paydas S, Elayoubi HR, Zaatari G, Zawam HM, and Zelenetz AD
- Subjects
- Africa, Northern epidemiology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Evidence-Based Medicine, Gallium Radioisotopes, Hodgkin Disease diagnosis, Hodgkin Disease therapy, Humans, Incidence, Lymphoma epidemiology, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin therapy, Middle East epidemiology, Positron-Emission Tomography, Tomography, X-Ray Computed, United States, Arabs statistics & numerical data, Lymphoma diagnosis, Lymphoma therapy
- Abstract
In the Middle East and North Africa (MENA) region, cancer has many epidemiologic and clinical features that are different from those in the rest of the world. Additionally, the region has a relatively young population and large disparities in the availability of resources at diagnostic and treatment levels. A critical need exists for regional guidelines on cancer care, including those for lymphoid malignancies. A panel of lymphoma experts from MENA reviewed the 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non-Hodgkin's Lymphoma and Hodgkin Lymphoma and suggested modifications for the region that were discussed with the United States NCCN Lymphoma Panels. This article presents the consensus recommendations.
- Published
- 2010
- Full Text
- View/download PDF
13. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
- Author
-
Giles FJ, Shan J, Chen S, Advani SH, Supandiman I, Aziz Z, Caviles AP, Tee GY, Chasen MR, Fahed Z, Chaoj TY, Aydogdu I, and Lynott AM
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Cytarabine administration & dosage, Cytarabine adverse effects, Female, Humans, Hydroxyurea administration & dosage, Hydroxyurea adverse effects, Interferon alpha-2, Interferon-alpha administration & dosage, Interferon-alpha adverse effects, Leukemia, Myeloid, Chronic-Phase mortality, Male, Middle Aged, Prospective Studies, Recombinant Proteins, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Chronic-Phase drug therapy
- Abstract
A prospective randomized international study of 143 patients showed no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy. Combinations of alpha-interferon (INF) and chemotherapeutic agents are currently first-line therapy for the majority of patients with chronic myeloid leukemia (CML). The International Oncology Study Group conducted a prospective randomized study comparing INF combined with hydroxyurea or cytarabine. The primary study aim was to compare the survival durations in these patient cohorts. Patients with early chronic phase CML were randomized to receive INF 5 million units (Mu) given five times per week subcutaneously plus hydroxyurea or cytarabine as required to achieve a complete hematologic response and to maintain a WBC count between 2x10(9)/L and 10x10(9)/L and a platelet count between 75x10(9)/L and 100x10(9)/L. Therapy continued as tolerated unless progressive or blast phase disease occurred. At 36 months, the actuarial survival rate was equivalent in both groups: HI group (79 patients) survival was 85% (95% CI, 68-100%), as compared to 95% (95% CI, 79-100%) in the CI group (64 patients). In conclusion if seems that there is no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.